JP2022533451A5 - - Google Patents

Info

Publication number
JP2022533451A5
JP2022533451A5 JP2021569550A JP2021569550A JP2022533451A5 JP 2022533451 A5 JP2022533451 A5 JP 2022533451A5 JP 2021569550 A JP2021569550 A JP 2021569550A JP 2021569550 A JP2021569550 A JP 2021569550A JP 2022533451 A5 JP2022533451 A5 JP 2022533451A5
Authority
JP
Japan
Prior art keywords
composition according
psen1
disease
promoter
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021569550A
Other languages
English (en)
Japanese (ja)
Other versions
JP7686573B2 (ja
JP2022533451A (ja
JP7686573B6 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/034040 external-priority patent/WO2020242892A1/en
Publication of JP2022533451A publication Critical patent/JP2022533451A/ja
Publication of JP2022533451A5 publication Critical patent/JP2022533451A5/ja
Publication of JP7686573B2 publication Critical patent/JP7686573B2/ja
Application granted granted Critical
Publication of JP7686573B6 publication Critical patent/JP7686573B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021569550A 2019-05-24 2020-05-21 アルツハイマー病のための遺伝子治療 Active JP7686573B6 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852716P 2019-05-24 2019-05-24
US62/852,716 2019-05-24
PCT/US2020/034040 WO2020242892A1 (en) 2019-05-24 2020-05-21 Gene therapy for alzheimer's disease

Publications (4)

Publication Number Publication Date
JP2022533451A JP2022533451A (ja) 2022-07-22
JP2022533451A5 true JP2022533451A5 (cg-RX-API-DMAC7.html) 2023-05-30
JP7686573B2 JP7686573B2 (ja) 2025-06-02
JP7686573B6 JP7686573B6 (ja) 2025-07-04

Family

ID=73553511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569550A Active JP7686573B6 (ja) 2019-05-24 2020-05-21 アルツハイマー病のための遺伝子治療

Country Status (8)

Country Link
US (1) US12540334B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976637A4 (cg-RX-API-DMAC7.html)
JP (1) JP7686573B6 (cg-RX-API-DMAC7.html)
CN (1) CN114144425B (cg-RX-API-DMAC7.html)
AU (1) AU2020285638A1 (cg-RX-API-DMAC7.html)
CA (1) CA3141712A1 (cg-RX-API-DMAC7.html)
IL (1) IL288266A (cg-RX-API-DMAC7.html)
WO (1) WO2020242892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019272848A1 (en) 2018-05-22 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
AU2020393917A1 (en) 2019-11-29 2022-06-23 Paros Bio, Inc. Gene therapy for neurodegenerative disorders
JP7849078B2 (ja) * 2022-01-29 2026-04-21 シャンハイ、レイジング、ファーマシューティカル、カンパニー、リミテッド Tpkを発現する組換えウイルスおよびアルツハイマー病の処置におけるその使用
JP2025527208A (ja) * 2022-07-25 2025-08-20 ヴィコ・セラピューティクス・ベー・フェー Appの異常なプロセシングに関連する疾患又は病態の治療用アンチセンスオリゴヌクレオチド

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JPH10501686A (ja) 1994-04-13 1998-02-17 ザ ロックフェラー ユニヴァーシティ 神経系の細胞へのdnaのaav仲介送達
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
WO1997027296A1 (en) 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
AR020107A1 (es) 1998-07-09 2002-04-10 Boehringer Ingelheim Pharma Metodo para identificar una sustancia capaz de reducir o eliminar la actividad de la presenilinasa, las sustancias identificables con dicho metodo, el usode estas ultimas en la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y las composiciones farmaceuticas que
JP2002520055A (ja) 1998-07-16 2002-07-09 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトプレセニリン関連タンパク質
US6979537B2 (en) 2000-01-10 2005-12-27 Scios, Inc. Methods for identifying inhibitors of neuronal degeneration
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7271313B2 (en) 2003-04-09 2007-09-18 The Brigham And Women's Hospital, Inc. Presenilin-deficient mouse model of age-dependent neurodegeneration and cognitive loss
CA2528963A1 (en) 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
WO2005037226A2 (en) 2003-10-17 2005-04-28 Georgia Tech Research Corporation Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders
CA2541523A1 (en) 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
WO2005096781A2 (en) 2004-04-06 2005-10-20 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using rna interference
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
CN101031658A (zh) 2004-05-26 2007-09-05 罗塞塔金诺米克斯有限公司 病毒和病毒相关mirna及其用途
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
WO2009042727A1 (en) 2007-09-24 2009-04-02 The Johns Hopkins University Immediate early gene arc interacts with endocytic machinery and regulates the trafficking and function of presenilin
AU2010316982B2 (en) 2009-11-09 2013-09-12 Genepod Therapeutics Ab Novel viral vector construct for neuron specific continuous DOPA synthesis in vivo
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
CN103816540B (zh) 2012-11-16 2018-01-02 中国科学院上海生命科学研究院 降低β‑抑制蛋白1与APH‑1蛋白的结合的物质在制备防治神经退行性疾病药物中的应用
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
WO2015006743A1 (en) 2013-07-12 2015-01-15 The Children's Hospital Of Philadelphia Aav vector and assay for anti-aav (adeno-associated virus) neutralizing antibodies
GB201404470D0 (en) 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
US10350245B2 (en) * 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
EP3270960A4 (en) 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
US10568516B2 (en) 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CA3025626A1 (en) 2016-05-27 2017-11-30 Transcriptx, Inc. Treatment of primary ciliary dyskinesia with synthetic messenger rna
WO2018045022A1 (en) 2016-08-30 2018-03-08 University Of South Florida Adipose derived stem cell exosomes and uses thereof
WO2018140532A1 (en) 2017-01-24 2018-08-02 Fred Hutchinson Cancer Research Center Systems and methods for hematopoietic cell expansion utilizing hydrogels
US11713470B2 (en) 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders
US11015204B2 (en) * 2017-05-31 2021-05-25 Arcturus Therapeutics, Inc. Synthesis and structure of high potency RNA therapeutics
US11512327B2 (en) * 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
AU2019272848A1 (en) 2018-05-22 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
AU2020393917A1 (en) 2019-11-29 2022-06-23 Paros Bio, Inc. Gene therapy for neurodegenerative disorders
EP4096786A4 (en) 2020-01-31 2024-04-10 Paros Bio, Inc. GENE THERAPY FOR NEURODEGENERATIVE DISORDERS USING POLYNUCLEOTIDE SILENCING AND REPLACEMENT

Similar Documents

Publication Publication Date Title
JP2021525245A5 (cg-RX-API-DMAC7.html)
CA2409674A1 (en) Glutamic acid decarboxylase (gad) based delivery systems
US11040113B2 (en) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with Friedreich ataxia
JP2020500526A5 (cg-RX-API-DMAC7.html)
JP2020533959A5 (cg-RX-API-DMAC7.html)
CN120324641A (zh) 用于治疗达农病的基因治疗载体
US20210108186A1 (en) Gene therapy for alzheimer`s disease
CN114144425B (zh) 用于阿尔茨海默症的基因治疗
WO2023093905A1 (zh) Aadc、gdnf多核苷酸及其用于治疗帕金森病
AU2021344607A9 (en) Methods for treating neurological disease
HUE028500T2 (en) The use of viral vectors carrying the CYPA46A1 gene for the treatment of Alzheimer's disease
Kou et al. Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer’s disease: prophylactic and therapeutic applications
WO2025038805A1 (en) Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
JP2022519596A (ja) Cln3ポリヌクレオチドのアデノ随伴ウイルス送達
TW202136515A (zh) 用於治療韓特氏病之腺相關病毒載體
Cardone Prospects for gene therapy in inherited neurodegenerative diseases
WO2023215266A1 (en) Bag3 and protein quality control in the brain
EP4347791A1 (en) Drug for genetic and gene-cell-based therapy
TWI888417B (zh) 用於抑制α-突觸核蛋白(SYNUCLEIN)表現之鋅指蛋白轉錄因子
JP7849078B2 (ja) Tpkを発現する組換えウイルスおよびアルツハイマー病の処置におけるその使用
JP2017123840A (ja) グルコーストランスポーター1発現用アデノ随伴ウイルスベクター
JP2024530050A5 (cg-RX-API-DMAC7.html)
TW202229320A (zh) 用於抑制α-突觸核蛋白(SYNUCLEIN)表現之新穎鋅指蛋白轉錄因子
CN115443145A (zh) 包括作为活性成分的甘氨酸转运体的用于治疗神经退行性脑病的药物组合物
CN118909979A (zh) 一种重组腺相关病毒AAV-Lec及其制备方法和应用